Product Description
a novel muscarinic receptor antagonist selective for urinary bladder over salivary gland (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30502343/)
Mechanisms of Action: M3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dong-A
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Korea
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Overactive Bladder
Phase 1: Healthy Volunteers|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DA8010_RI_I | P1 |
Completed |
Kidney Diseases |
2024-06-07 |
|
| DA8010_DIPM_I | P1 |
Completed |
Healthy Volunteers |
2023-11-07 |
28% |
| DA8010_DIPM_I | P1 |
Completed |
Healthy Volunteers |
2023-11-07 |
28% |
| DA8010_DICR_I | P1 |
Completed |
Healthy Volunteers |
2023-11-06 |
28% |
| DA8010_OAB_III | P3 |
Completed |
Overactive Bladder |
2023-11-01 |